KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbbVie (ABBV) Equity Average (2016 - 2026)

AbbVie has reported Equity Average over the past 13 years, most recently at -$2.9 billion for Q4 2025.

  • Quarterly Equity Average fell 162.47% to -$2.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.9 billion through Dec 2025, down 162.47% year-over-year, with the annual reading at $48.5 million for FY2025, 99.29% down from the prior year.
  • Equity Average was -$2.9 billion for Q4 2025 at AbbVie, down from -$1.4 billion in the prior quarter.
  • Over five years, Equity Average peaked at $16.7 billion in Q4 2022 and troughed at -$2.9 billion in Q4 2025.
  • The 5-year median for Equity Average is $12.8 billion (2021), against an average of $9.8 billion.
  • Year-over-year, Equity Average soared 272.13% in 2021 and then tumbled 162.47% in 2025.
  • A 5-year view of Equity Average shows it stood at $14.5 billion in 2021, then rose by 14.82% to $16.7 billion in 2022, then tumbled by 32.38% to $11.3 billion in 2023, then tumbled by 58.29% to $4.7 billion in 2024, then tumbled by 162.47% to -$2.9 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Equity Average are -$2.9 billion (Q4 2025), -$1.4 billion (Q3 2025), and $662.0 million (Q2 2025).